Thalidomide-5-O-CH2-COOH is a high-purity E3 Ligase Ligand-Linker Conjugate specifically designed for use in PROTAC (Proteolysis Targeting Chimera) drug discovery and development. This compound features thalidomide as the cereblon (CRBN) E3 ligase-recruiting ligand, functionalized with a carboxylic acid linker at the 5-O position. Thalidomide-5-O-CH2-COOH is an essential building block for synthesizing PROTACs, allowing researchers to connect various target protein ligands and develop novel, bifunctional molecules capable of targeted protein degradation. As PROTACs harness the ubiquitin-proteasome system by recruiting E3 ligases like CRBN to initiate selective proteolysis of disease-relevant proteins, this ligand-linker conjugate facilitates customization for diverse therapeutic applications, including oncology, neurodegeneration, and beyond. Ideal for academic and pharmaceutical researchers, this intermediate streamlines the assembly of tailor-made PROTACs with enhanced selectivity and potency.
Structure of 2467425-53-0
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Thalidomide-5-O-CH2-COOH is a chemically modified derivative of thalidomide, designed specifically as a functional E3 ligase ligand-linker conjugate. This molecule strategically incorporates a carboxylic acid group into thalidomide’s 5-position via a methylene spacer, facilitating efficient conjugation to additional components for targeted protein degradation applications. E3 ligase ligands play a pivotal role in the development of PROTACs (Proteolysis Targeting Chimeras), enabling the selective degradation of disease-relevant proteins.
Mechanism
The primary mechanism of Thalidomide-5-O-CH2-COOH involves its function as a cereblon (CRBN) E3 ubiquitin ligase recruiting element. When incorporated into PROTACs, the thalidomide-based ligand binds CRBN, forming part of an induced ternary complex with the target protein and E3 ligase. The carboxylic acid linker allows chemical attachment to a targeting ligand via amide or ester bond formation, effectively bringing the E3 ligase and the protein of interest into close spatial proximity. This proximity promotes ubiquitination and subsequent proteasomal degradation of the target protein, resulting in precise and efficient protein knockdown.
Applications
Thalidomide-5-O-CH2-COOH is widely utilized as a modular building block in the synthesis of PROTAC molecules, molecular glues, and other targeted protein degradation compounds. Its enhanced reactivity and optimal linker position make it ideal for conjugation with a variety of ligands targeting oncology, neurology, or immunology-relevant proteins. Researchers employ this conjugate in preclinical studies for the rational design of next-generation therapeutics, high-throughput screening of degrader libraries, and expanding the coverage of druggable proteomes. Thus, it serves as a key reagent in both academic and industrial research aimed at developing novel small molecule degraders.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.